Over 90 million people in the US suffer from some form of organ or tissue failure. Diseases such as Diabetes (failure of pancreatic tissue to produce insulin), Lung, Liver and Kidney disease have only high-cost, high risk, and low availability options such as organ transplantation, dialysis, oxygen therapy, or daily injections. These patients face a life of palliative care, and high intervention costs.
Prellis Biologics, Inc. has developed a patented technology that solves the last major hurdle in human organ and tissue engineering: the rapid creation of microvasculature (capillaries). Without microvasculature tissues thicker than a couple of sheets of paper (300 micrometers) rapidly become hypoxic and the cells begin to die off within minutes.
Prellis Biologics envisions a future in which a patient’s own cells are used to re-populate vascularized tissue structures to replace organs and diseased tissues, thus offering a cost-effective long-term solution to numerous chronic diseases. Our mission is to reshape the future of health and medicine by producing fully vascularized human tissue and organs for transplantation.
Prellis Biologics, Inc. was founded in 2016 in San Francisco, California.